Document:

EXHIBIT 10.2

 

	Marketing
    Company Agreement

 

NHS
PHARMA SALES, Inc.

 

THIS
AGREEMENT, entered into as of January 26, 2015 (the “Effective Date”) by and between NHS PHARMA SALES
INC., a corporation organized and existing under the laws of the State of California (hereinafter referred to as “NHSPS”
or the “Company”) whose legal address is 1323 W Colton Ave Suite 120, Redlands, CA 92374, and MESA PHARMACY
INC a corporation organized and existing under the laws of the state of California, (hereinafter referred to as MESA)
whose legal address is 18013 Sky Park Circle, Suite D Irvine, CA 92614.

 

WHEREAS,
NHSPS is engaged in the marketing, sale and distribution of pharmaceutical products and related accessories suitable for pharmacies.

 

WHEREAS,
NHSPS and MESA desire to enter into a relationship, whereby NHSPS will promote the sale of MESA’s
products and services in the geographical areas where MESA has a viable State Pharmacy License (collectively, the “Services”),
upon the terms and conditions hereinafter set forth.

 

NOW,
THEREFORE, it is mutually agreed upon as follows:

 

1.
TERRITORY:

 

The
NHSPS’s territory in conducting the Services will consist of the geographical area described below:

 

The entire United States
of America

 

It
is understood that NHSPS has the right to appoint additional marketing representatives to perform the Services in
NHSPS’s territory (the “NHSPS
Groups”); NHSPS understands that it does not have an exclusive territory.

 

2.
DUTIES OF NHSPS

 

NHSPS
will use its best efforts to solicit orders for the sale of compounded medications for MESA. NHSPS, and the NHSPS
Groups, shall offer these products in a clear, understandable and professional manner. In this regard, NHSPS, and the
NHSPS Groups, will present MESA products and accessories to physicians, health facilities, direct and indirect personnel,
hospitals, and consumers within the NHSPS’s territory. NHSPS, and the NHSPS Groups, will at all times
emphasize and adhere to all regulations and practices relating to user safety, shall at all times maintain a professional appearance
and shall provide after-sales service to any customer who has purchased or purchases products and accessories in accordance with
this Agreement and applicable laws. Additionally, NHSPS, and the NHSPS Groups, through their independent contractor
or employment relationship with NHSPS, must submit all physicians’ names, addresses, phone numbers, and an original
script ordered from the physician, once the original script has been issued from the physician the account will then be deemed
to be an NHSPS exclusive account. At any time during the calendar year if the physician does not write a script for any
period longer than 59 calendar days the physician will be deemed to be “available” to other marketing representatives,
to solicit services and products and sign up the physicians on behalf of MESA.

 

    	Page | 1

    	 

    

  

	Marketing
    Company Agreement

 

3.
PRECRIPTIONS

 

All
NHSPS’ solicitations for MESA’s products and/or accessories will be conducted in accordance with such
procedures, and terms and conditions as MESA may specify from time to time, and applicable laws. All medical prescriptions
or sales orders are subject to MESA’s approval.

 

4.
AGENCY

 

NHSPS
is an independent contractor, and under no circumstances will NHSPS commit to the delivery of MESA products
and/or accessories, or purport to legally bind MESA in any matter, or hold itself out as an agent with legal authority
to bind MESA without MESA’s prior written consent. All accepted Prescriptions, i.e., MESA’s products
and/or accessories, whether or not delivery dates are specified, shall be subject to delays in manufacture or delivery due to
any cause beyond MESA’s reasonable control. NHSPS, and the NHSPS Groups may include the MESA
logo on the bottom of their business card, however a sample must be submitted to MESA prior to the printing of the same
for written approval.

 

5.
RULES OF CONDUCT

 

In
the course of representing MESA, NHSPS, and the NHSPS Groups shall adhere to the following rules of conduct, which
include, but are not limited to:

 

(a)
NHSPS, and the NHSPS Groups, shall not disparage, denigrate, “run down” or make any negative comments
regarding another manufacturer or competitors’ product or service.

 

(b)
NHSPS, and the NHSPS Groups, shall not solicit or sell MESA products and/or accessories, or enter into a
type of arrangement, wherein the sale of MESA products is made conditional in any way on a user’s purchase of another
company’s products.

 

(c)
Each NHSPS representative, and the NHSPS Groups, shall at all times maintain a professional appearance and shall
not perform any of his duties set forth in this agreement, while intoxicated in any manner or under the influence of any illegal
drug.

 

(d)
NHSPS, and the NHSPS Groups, shall comply with all applicable laws while performing the Services. The parties will
execute a Business Associate Addendum, to address any protected health information to which NHSPS, and the NHSPS Groups,
may require access to perform its duties under this Agreement.

 

(e)
Under no circumstances shall the NHSPS, and/or the NHSPS Groups market, sell or demonstrate MESA products and accessories
together with any after-market product that has not been approved by MESA.

 

(e)
NHSPS understands and agrees that any failure to enforce the paragraphs contained in section 5 of this Agreement is not
to be considered a waiver of MESA’s rights hereunder and NHSPS, and each NHSPS representative, and
NHSPS Group, hereby waives any right to the defense of waiver.

 

Any
violation of any of the above provisions shall be grounds for immediate termination of this Agreement by MESA.

 

    	Page | 2

    	 

    

 

	Marketing
    Company Agreement

 

6.
PERSONNEL

 

NHSPS
shall not use any person to perform any duties under this Agreement, unless said person/NHSPS Group has completed
all the following:

 

(a)
Successfully passed the MESA presentation and Product Training Course, and any other tests or courses deemed necessary
to perform the duties as provided herein.

 

(b)
Received MESA’s prior approval to market its products and/or accessories.

 

If
any person employed by, or affiliated with NHSPS, or the NHSPS Group, performs any duties not approved by MESA,
NHSPS shall waive its right to receive commissions and MESA shall have the right to immediately terminate this Agreement.
NHSPS agrees and understands that MESA may, at any time, request that a member of NHSPS, and/or any of the
NHSPS Groups, take and successfully complete educational courses in order to perform the Services.

 

7.
USE OF INFORMATION

 

Only
approved information, and terms and conditions by MESA will be used in any advertising, sales promotions, solicitation
and other duties set forth in this Agreement, NHSPS, nor the NHSPS Groups, will undertake to design or re-engineer
MESA products and/or accessories, or advise any person on any technical specification, training practices, bulletins, or
accepted practices of MESA.

 

IN
THE EVENT NHSPS, AND/OR THE NHSPS GROUPS, ADVISES ANY PERSON CONTRARY TO MESA POLICIES, SPECIFICATIONS, TERMS AND CONDITIONS OR
PROCEDURES CONCERNING MESA’S PRODUCT LINE, OR THE PROPER USE OF MESA’S PRODUCTS, OR INDUCES ANY PERSON TO USE OR APPLY
MESA’S PRODUCTS BY MISREPRESENTATION OF THE PRODUCT, ITS CHARACTERISTICS, USE, COST, AVAILABILITY, SAFETY OR APPLICATIONS,
NHSPS SHALL INDEMNIFY, DEFEND, PAY, SAVE AND HOLD MESA HARMLESS FROM ANY AND ALL CLAIMS, COSTS, JUDGEMENTS, AND DAMAGES, INCLUDING
REASONABLE ATTORNEY’S FEES AND EXPENSES OF COUNSEL, WHICH ARE INCURRED AS A DIRECT OR INDIRECT CONSEQUENCE THEREOF.

 

8.
REPORTING AND SALES FORECASTS

 

NHSPS
must upon request, quarterly and as soon as available provide MESA with:

 

(a)
Available market information including, but not limited to, pricing on related products and applicable accessories, new product
information, associated costs, procedures, and problem areas. Notwithstanding the forgoing, in no event shall the above information
or any other information be obtained from sources that are in direct competition with MESA. In no event shall the above
information be released, disclosed, or disseminated in any way to anyone other than MESA during the Term of this Agreement,
and for a period of two (2) years thereafter, without MESA’s prior written consent.

 

(b)
Forecasts by territory, with respect to the total number of physicians expected to be sold (broken down and separated by specialty
and sales, by state). These forecasts will be updated at least every 3 months or sooner, If a moderate market change occurs, that
impacts the sales forecast and production schedule. Failure to make satisfactory progress toward meeting sales forecasts and previously
agreed upon sales goals shall be grounds for termination of this Agreement by MESA.

 

    	Page | 3

    	 

    

 

	Marketing
    Company Agreement

  

9.
COMMISSIONS

 

Subject
to the terms and conditions of this Agreement, NHSPS will receive a commission on sales (third party insurance reimbursement)
in accordance with the following schedule:

 

(a)
NHSPS will receive a commission of 55% of total amount committed to the pharmacy
from the Insurance payor from prescriptions and refills that have been generated by the Services NHSPS provides to MESA. In
the event that MESA receives a no pay from the Insurance payor for a non-covered patient, or a non-covered medication,
or a no pay for a Medlcare/Medicaid product, then there is no commission due to the Sales Rep. Commissions on the total
commissionable sales shall be paid to NHSPS twice a month. NHSPS will submit an invoice to MESA on
the 3rd and 18th of every month and payment is due upon receipt. The committed prescriptions from the 1st
of the month to the 15th will be invoiced on the 18th and the committed prescriptions from the 15th
to the 30th will be invoiced on the 3rd.

 

(b)
Any dispute or claim by NHSPS with respect to the entitlement and/or amount of commissions shall be made in writing to
MESA within forty-five (45) days from the end of the month for which commissions are claimed as to entitlement and/or amount.
Failure to timely raise in writing any claims or disputes with respect to entitlement or amount shall constitute a total waiver
by NHSPS for any such commissions.

 

(c)
The parties intend that the compensation due under this Agreement shall be consistent with applicable laws. The compensation set
forth herein is based on an agreement of the parties as to the fair market value
for the Services. The parties have made such investigation as is necessary to satisfy themselves as to the appropriateness of
the levels of compensation. To the extent that any change in law, regulation or judicial
Interpretation of applicable law would render any element of compensation hereunder to be illegal, upon the request of either
party, the parties shall confer promptly to negotiate an adjustment to the relevant element of compensation or modification of
the Services to conform to the law. If the parties are unable to agree upon an adjustment to compensation or modification of the
services, then either party may give notice of termination of this Agreement in accordance with Section 19(c) hereof.

 

(d)
NHSPS, and the NHSPS Groups, shall be responsible for the payment of all expenses that it incurs in the provision of the Services
and all taxes, whether based on income, payroll or otherwise, that may be imposed on the commissions paid hereunder. MESA
shall have no obligation to reimburse or pay any expenses on behalf of NHSPS, and/or the NHSPS Groups, unless approved
by MESA prior to such expenditure.

 

10.
THIS SECTION HAS SEEN LEFT INTENTIONALLY BLANK.

 

11.
SAMPLES

  

Any
samples provided to NHSPS shall remain the property of MESA, cannot be sold or transferred to any other person and
must be returned upon request. It shall be the responsibility of NHSPS, and/or the NHSPS Group principal, to ensure
that each representative, who is active, has in his or her possession, or has readily
available access to a complete line of MESA’s products. All samples are subject to review at any time by MESA
and under no circumstances may be sold, transferred, conveyed, pledged, or hypothecated to any individual or any other
entity, unless approved in advance in writing by MESA. Failure of NHSPS to maintain samples in a perfect working
order shall be a cause to immediately terminate this Agreement by MESA.

 

    	Page | 4

    	 

    

 

	Marketing
    Company Agreement

 

12.
TRADE SHOWS AND CONVENTIONS

 

NHSPS
will from time to time take booth space at conventions and
will have certain sales representatives attend on behalf of MESA, but only if authorized in advance by MESA.

 

13.
MEETINGS

 

NHSPS
may from time to time attend national trade show meetings, shows, or training programs if requested by MESA.

 

14.
TECHNICAL SUPPORT AND INSURANCE

 

NHSPS
shall provide technical and training support and insurance as needed.

 

15.
SUBCONTRACTING OR ASSIGNMENT

 

It
is agreed that subcontracting or assignment of this Agreement may happen only by the mutual written consent of the parties. Under
no circumstances will NHSPS subcontract, assign, delegate or otherwise have any person or entity perform any of the duties
and obligations of NHSPS under this Agreement without MESA’s express written consent.

 

16.
GOVERNING LAW

 

This
Agreement shall be deemed to have been made in California and shall be governed and construed in accordance with the laws of the
State of California. Should a disagreement arise over any of the provisions relating to this Agreement, NHSPS and MESA
shall first meet to make a good faith effort to settle any dispute. If this meeting is unsuccessful, both parties hereby agree
that any unresolved dispute shall be settled in binding arbitration under the rules of the American Arbitration Association. Specifically,
this Agreement sets forth the entire understanding and agreements of the parties hereto with respect to the subject matter hereof
and supersedes all other representations and understandings both written and oral. This Agreement is drafted under the laws of
the state of California, and the venue for any legal recourse shall take place under laws as written in California, and the venue
for any legal recourse shall take place under these laws and be adjudicated within its jurisdiction. Further, the parties agree
that any controversy or claim arising out of, or relating to, this agreement, or the breach thereof, shall be settled by binding
arbitration with the American Arbitration Association, and in accordance with the rules of the American Arbitration Association
in the state of California, under their auspices and the parties agree to have any dispute heard and adjudicated under these rules
in the state of California, and both parties agree to be bound by the decision of the arbitrator and to pay their proportionate
fees as required under the rules of the association and judgment upon the award rendered by the arbitrator(s) may be entered into
any court having jurisdiction thereof.

 

    	Page | 5

    	 

    

 

	Marketing
    Company Agreement

 

17.
TERM

 

This
Agreement shall be effective as of the Effective Date, and the initial term of this Agreement shall be for one year (the “Term”),
terminating on January 26, 2016 (“Termination Date”).

 

Not
less than sixty (60) days prior to January 26 of each year, commencing with January 26, 2015 (each, a “Renewal Date”),
the parties hereto shall each have the right to propose a renewal of this Agreement for an additional term of one (1) year. Such
receiving party shall then have thirty (30) days thereafter to accept or decline the proposed renewal; provided however that the
failure by the receiving party to accept the renewal term within the thirty (30) day response period shall be deemed to be a rejection
of the proposed renewal term and this Agreement shall terminate as of the end of the then current term.

 

18.
DISPUTES

 

As
described in detail in paragraph 17 hereof, any claim, matter or controversy arising out of or relating to this Agreement, or
the breach thereof, shall be decided by binding arbitration with and under the rules of the American Arbitration Association.

 

19.
TERMINATION

 

Except
as otherwise specified herein:

 

(a)
Termination for Cause by Either Party. Except as provided in Sections (b)
and (c) below, either party may terminate this Agreement for cause upon written notice to the other party specifying the nature
of the alleged breach of this Agreement. For purposes of this Agreement, “cause” shall be construed to mean a material
breach of an obligation to be performed hereunder, that is not cured within thirty (30) days or for which reasonable steps to
cure are not undertaken and diligently and continuously pursued if such cure cannot reasonably be achieved during such thirty
(30) day period.

 

(b)
Bankruptcy. Either party may terminate this Agreement effective immediately
upon written notice, if the other party files a petition in bankruptcy is adjudicated bankrupt, or takes advantage of the insolvency
laws of any jurisdiction, makes an assignment for the benefit of creditors, is voluntarily or involuntarily dissolved, or has
a receiver, trustee, or other court officer appointed with respect to its property.

 

(c)
Violation of law. Either party may terminate this Agreement immediately
upon written notice, if the other party is operating in violation of any law that governs this Agreement unless the parties are
unable to negotiate an adjustment to the compensation or modification to the Services in accordance with Section 3.3 to conform
to the requirements of the law and address all legal obligations related to the violation.

 

(d)
Termination without Cause. Either party may terminate this Agreement without
cause upon giving ninety (90) days’ written notice to the other party.

 

(e)
Effects of Termination. Upon termination of this Agreement, as provided herein,
neither party shall have any further obligations hereunder except for (a) obligations accruing prior to the date of termination,
and (b) obligations, promises, or covenants contained herein that are expressly made to extend beyond the Term of this Agreement.
The termination of the Agreement shall not relieve either party of duties or obligations to promptly account for and pay to the
other all amounts due under this Agreement through the date of such termination; provided that in the event of a termination in
accordance with section (c) above, the parties’ obligations shall be limited by conformity to applicable law, i.e., neither
party shall be entitled to performance of any obligation or payment of any amount that would constitute a violation of law.

 

    	Page | 6

    	 

    

 

	Marketing
    Company Agreement

  

20.
CONFIDENTIALITY

 

The
parties understand and acknowledge that during the Term of this Agreement they may receive or have access to information of a
proprietary and confidential nature concerning the other party or the subject matter of this Agreement. “Confidential Information”
shall mean all information designated in writing by a party to be confidential and all information concerning a party that is
not otherwise publicly available, including but not limited to contents of any of the Products, computer codes, software applications,
customer names, and pricing information. The parties shall use Confidential Information of the other solely for the purposes of
this Agreement and enforce appropriate restrictions on their authorized employees or agents who need to know such information
to carry out the terms of this Agreement. Upon the termination of this Agreement, each party will deliver to the other party any
Confidential Information of the other, whether delivered or created pursuant to this Agreement. No party shall retain any of the
other party’s Confidential Information, and upon written request, shall certify in writing to the return or destruction
of such Confidential Information. This covenant concerning Confidential Information shall survive the termination of this Agreement
for a period of two (2) years.

 

21.
ENTIRE AGREEMENT

 

This
Agreement embodies the entire agreement between the parties hereto, and there are no verbal or collateral agreements between them.
All preliminary negotiations, representation and discussions are deemed merged herein. This Agreement may be altered or modified
only in writing and signed by all parties hereto.

 

22. NOTICES

 

All
notices, requests and other communications hereunder shall be in writing and shall be deemed to have been given only if mailed,
certified return receipt request, or if sent by a well-recognized private delivery service or if personally delivered to, or if
sent by fax or electronic mail with the original thereby sent by a means as specified below:

 

If
to NHSPS:

NHS
Pharma Sales Inc.

1323 W Colton
Ave Suite 120

Redlands,
CA 92374

Attn:
Charles Ronald Green, Jr.

Fax:
909.666-5300

 

If
to MESA:

Mesa Pharmacy, Inc.

18013
Sky Park Cir, Suite D

Irvine,
CA 92614

Attn: Edward Kurtz

Fax: (949) 955-2925

 

    	Page | 7

    	 

    

 

	Marketing
    Company Agreement

 

All
notices, requests and other communications shall be deemed received on the date of acknowledgment or other evidence of actual
receipt in the case of certified mail, courier delivery or personal delivery, or in the case of fax delivery or electronic mail,
upon the date of fax receipt or the date of the electronic mail, provided the original is delivered within two (2) business days.
Any party hereto may designate different or additional parties for the receipt notice, pursuant to notice given In accordance
with the foregoing.

 

IN
WITNESS WHEREOF, the parties have executed this Agreement in Redlands, CA, as of the Effective Date hereof.

  

	 	NHS
    PHARMA SALES, INC.	 	 	MESA
    PHARMACY, INC.
	 	 	 	 	 
	By:		 	By:	
	Print:	Charles
    Ronald Green, Jr.	 	Print:	Edward
    Kurtz
	Address:
    	1323
    W. Colton Ave., Suite 120 

    Redlands, CA 92374	 	Address:
    	18013 Sky Park
    Circle, Suite A

    Irvine, CA 92614

 

    	Page | 8Exhibit 4(a)(2)

Amendment No. 1 to the Investment Management
Agreement

This Amendment No. 1 to the Investment
Management Agreement dated as of November 21, 2014 (the “Amendment”) is entered into by and between BlackRock Bond
Fund, Inc., a Maryland corporation (the “Corporation”), on behalf of BlackRock Total Return Fund (the “Fund”),
and BlackRock Advisors, LLC, a Delaware limited liability company (the “Adviser”).

WHEREAS, the Corporation, on behalf of
the Fund, and the Adviser have entered into an Investment Management Agreement dated as of September 29, 2006 (the “Management
Agreement”) pursuant to which the Adviser agreed to act as investment adviser to the Fund; and

WHEREAS, the Management Agreement provides
that the Corporation, on behalf of the Fund, will pay to the Adviser a monthly fee in arrears at an annual rate equal to the amount
set forth in Schedule A thereto; and

WHEREAS, the Management Agreement may be
amended in accordance with Section 14 of the Management Agreement; and

WHEREAS, the Board of Directors, including
a majority of those Directors who are not interested persons of the Corporation, approved an amendment to the Management Agreement
as set out in this Amendment at an in-person meeting held on November 11, 2014.

NOW, THEREFORE, the parties hereto, intending
to be legally bound, hereby agree as follows:

		1.	Schedule A of the Management Agreement is hereby amended as set forth on the Appendix A attached hereto with respect to the
Fund.

 

		2.	Except as otherwise set forth herein, the terms and conditions of the Management Agreement shall remain in full force and effect.

 

[End of Text]

    	 

    	 

    

 

IN WITNESS WHEREOF, the parties hereto have caused
this Amendment No. 1 to the Investment Management Agreement to be executed by their officers designated below as of the day and
year first written above.

 

 

 

	 	BLACKROCK BOND FUND, INC.
	 	 
	 	 
	 	By:	     /s/ John M. Perlowski
	 	 	Name: John M. Perlowski
	 	 	Title: President and Chief Executive Officer
	 	 	 
	 	 	 
	 	BLACKROCK ADVISORS, LLC
	 	 
	 	 
	 	By:	     /s/ Neal J. Andrews
	 	 	Name: Neal J. Andrews
	 	 	Title: Managing Director

    	- 2
                                                                                                                                                                                                                                  -

    	 

    

 

APPENDIX A

 

 

 

	
        Portfolio
	
        Advisory
Fee

(as a percentage of average

daily net assets)1
	
        Advisory
Fee

(as a percentage of average

daily net assets)2

	BlackRock Total Return Fund	First $250 million	32%	First $250 million	48%
	 	$250 million - $500 million	31%	$250 million - $500 million	43%
	 	$500 million - $750 million	30%	$500 million - $750 million	38%
	 	Over $750 million	29%	Over $750 million	34%
	 	 	 	 

 

		1	This contractual management fee breakpoint schedule applies to BlackRock Total Return Fund for as long as BlackRock Total Return
Fund invests substantially all of its assets in Master Total Return Portfolio, a series of Master Bond LLC, or another master fund
advised by the Adviser or an affiliate thereof in a master-feeder structure (a “Master Fund”).

		2	This contractual management fee breakpoint schedule applies to BlackRock Total Return Fund in the event that BlackRock Total
Return Fund does not invest in a Master Fund (i.e., operates as a standalone fund).

    	- 3
                                                                                                                                                                                                                                  -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}]]